Allogene Therapeutics Inc [NASDAQ: ALLO] surged by $0.07 during the normal trading session on while it closed the day at $2.20.
Allogene Therapeutics Inc stock has also gained 5.26% of its value over the past 7 days. However, ALLO stock has declined by -13.04% in the 3 months of the year. Over the past six months meanwhile, it has gained 5.77% and gained 3.29% year-on date.
The market cap for ALLO stock reached $461.28 million, with 209.50 million shares outstanding and 142.63 million shares in the current float. Compared to the average trading volume of 2.40M shares, ALLO reached a trading volume of 3451956 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Allogene Therapeutics Inc [ALLO]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ALLO shares is $9.96 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ALLO stock is a recommendation set at 1.56. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Oppenheimer have made an estimate for Allogene Therapeutics Inc shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on August 08, 2024. While these analysts kept the previous recommendation, Piper Sandler raised their target price to Overweight. The new note on the price target was released on May 31, 2024, representing the official price target for Allogene Therapeutics Inc stock.
The Average True Range (ATR) for Allogene Therapeutics Inc is set at 0.18, with the Price to Sales ratio for ALLO stock in the period of the last 12 months amounting to 11531.92. The Price to Book ratio for the last quarter was 0.99, with the Price to Cash per share for the same quarter was set at 1.39.
ALLO stock trade performance evaluation
Allogene Therapeutics Inc [ALLO] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 5.26. With this latest performance, ALLO shares dropped by -13.73% in over the last four-week period, additionally plugging by 5.77% over the last 6 months – not to mention a drop of -39.23% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ALLO stock in for the last two-week period is set at 50.86, with the RSI for the last a single of trading hit 56.27, and the three-weeks RSI is set at 48.46 for Allogene Therapeutics Inc [ALLO]. The present Moving Average for the last 50 days of trading for this stock 2.40, while it was recorded at 2.16 for the last single week of trading, and 2.76 for the last 200 days.
Allogene Therapeutics Inc [ALLO]: An insightful look at the core fundamentals
Allogene Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 9.35 and a Current Ratio set at 9.35.
Earnings per share (EPS) analysis for Allogene Therapeutics Inc [ALLO] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ALLO. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Allogene Therapeutics Inc go to 1.00%.
Allogene Therapeutics Inc [ALLO]: Institutional Ownership
There are presently around $80.21%, or 97.13%% of ALLO stock, in the hands of institutional investors. The top three institutional holders of ALLO stocks are: FMR LLC with ownership of 31.26 million shares, which is approximately 18.4816%. TPG GP A, LLC, holding 18.72 million shares of the stock with an approximate value of $$43.61 million in ALLO stocks shares; and TPG GP A, LLC, currently with $$38.32 million in ALLO stock with ownership which is approximately 9.7238%.
